Antibodies as Drugs: From B Cell Biology to New Treatments Organizer(s): Paul Carter, Janine Schuurman and Karl Dane Wittrup Date: February 02 - 06, 2020
Location: Eldorado Hotel & Spa, Santa Fe, NM, USASince the mid-1990s, antibodies have grown steadily into a clinically important pharmaceutical class with over 70 antibody-based drugs approved, predominantly in oncology, autoimmunity and inflammation. As the antibody drug field has expanded and matured in recent years, the field has moved from empirical strategies to deep knowledge-based, designer approaches for which understanding of mechanisms of action is critical; there has also been a trend toward increasingly specialized meetings with a narrow focus such as cancer immunotherapy, bispecifics or B cell biology. In contrast, we are proposing a scientifically diverse program that spans a broad range of different and cutting-edge topics relevant to antibody drug development, including antibodies for infectious disease and antibody pharmacology, topics which are often under-represented at major antibody conferences. Additionally, we have chosen a diverse collection of speakers from junior investigators to seasoned researchers from a wide range of institutions in at least eight different countries. We hope and expect that this approach will stimulate ‘cross-pollination’ between disciplines that span the gamut from basic to translational to clinical sciences with the common theme of antibody drugs for the benefit of patients. Scholarship Deadline: October 17 2019 Discounted Abstract Deadline: October 17 2019 Abstract Deadline: November 5 2019 Discounted Registration Deadline: December 5 2019 We gratefully acknowledge additional support from these exhibitors at this conference:  We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Adimab, Inc.
Akrevia Therapeutics
Genentech, Inc.
Genmab A/S
Immatics Biotechnologies GmbH
Light Chain Bioscience
Regeneron Pharmaceuticals, Inc.
|